Friday, March 29, 2024
ADVT 
Health

Gilead's $2,340 price for coronavirus drug draws criticism

Darpan News Desk The Canadian Press, 29 Jun, 2020 10:08 PM
  • Gilead's $2,340 price for coronavirus drug draws criticism

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

“We’re in uncharted territory with pricing a new medicine, a novel medicine, in a pandemic,” Gilead’s chief executive, Dan O’Day, told The Associated Press.

“We believe that we had to really deviate from the normal circumstances” and price the drug to ensure wide access rather than based solely on value to patients, he said.

However, the price was swiftly criticized; a consumer group called it “an outrage” because of the amount taxpayers invested toward the drug's development.

The treatment courses that the company has donated to the U.S. and other countries will run out in about a week, and the prices will apply to the drug after that, O'Day said.

In the U.S., federal health officials have allocated the limited supply to states, but that agreement with Gilead will end after September. They said Monday that the government has secured more than 500,000 additional courses that Gilead will produce starting in July to supply to hospitals through September, and stressed that that does not mean the government actually was acquiring that much, just ensuring the availability.

“We should have sufficient supply ... but we have to make sure it’s in the right place at the right time," O’Day said

In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug; two countries are doing that for around $600 per treatment course.

Remdesivir’s price has been highly anticipated since it became the first medicine to show benefit in the pandemic, which has killed more than half a million people globally in six months.

The drug, given through an IV, interferes with the coronavirus’s ability to copy its genetic material. In a U.S. government-led study, remdesivir shortened recovery time by 31% — 11 days on average versus 15 days for those given just usual care. It had not improved survival according to preliminary results after two weeks of followup; results after four weeks are expected soon.

The Institute for Clinical and Economic Review, a non-profit group that analyzes drug prices, said remdesivir would be cost-effective in a range of $4,580 to $5,080 if it saved lives. But recent news that a cheap steroid called dexamethasone improves survival means remdesivir should be priced between $2,520 and $2,800, the group said.

“This is a high price for a drug that has not been shown to reduce mortality,” Dr. Steven Nissen of the Cleveland Clinic said in an email. “Given the serious nature of the pandemic, I would prefer that the government take over production and distribute the drug for free. It was developed using significant taxpayer funding.”

Peter Maybarduk, a lawyer at the consumer group Public Citizen, called the price “an outrage.”

“Remdesivir should be in the public domain” because the drug received at least $70 million in public funding toward its development, he said.

“The price puts to rest any notion that drug companies will ‘do the right thing’ because it is a pandemic,” Dr. Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in New York said in an email. “The price might have been fine if the company had demonstrated that the treatment saved lives. It didn’t.”

While it may be a sticker shock for many, “from the health system perspective, if remdesivir can shorten duration of hospitalization by four days, then the medicine provides a reasonable value,” Dr. David Boulware, an infectious disease specialist at the University of Minnesota, said in an email.

O’Day said that shortening hospitalization saves about $12,000 per patient. Gilead says it will have spent $1 billion on developing and making the drug by the end of this year. Gilead shares rose 64 cents to $75.22 in late-morning trading.

The drug has emergency use authorization in the U.S. and Gilead has applied for full approval.

Jefferies pharmaceuticals analyst Michael Yee wrote to investors that Gilead’s price was a bit above what stock brokers were expecting. He said that at that price, analysts expect Gilead to make $525 million on remdesivir sales this year and $2.1 billion next year.

MORE Health ARTICLES

Advocates worry pandemic's 'perfect storm' puts more kids at risk for abuse

Advocates worry pandemic's 'perfect storm' puts more kids at risk for abuse
OTTAWA — Reports to authorities about suspected child abuse or neglect are down as much as 40 per cent in some regions but child advocates say it's not because fewer kids are at risk.

Advocates worry pandemic's 'perfect storm' puts more kids at risk for abuse

Ask a Designer: Improving your home's function as refuge

Ask a Designer: Improving your home's function as refuge
When your entire life is happening inside your home, it matters how that space feels and functions. Interior designers often focused on this even before self-quarantine, asking clients how they spend their time at home and how various rooms might make them happier. These questions get at the real purpose of a well-designed home.

Ask a Designer: Improving your home's function as refuge

'We're the pioneers': Canadian COVID-19 survivors share their stories

'We're the pioneers': Canadian COVID-19 survivors share their stories
We all know we should be afraid of it, but relatively few Canadians have experienced COVID-19 themselves.   The effort to contain the pandemic has wrought seismic disruptions to daily life on an individual and global scale. But even as the number of cases in Canada climbs, it's hard to comprehend the contagion based on a list of symptoms and warnings that it's fatal.

'We're the pioneers': Canadian COVID-19 survivors share their stories

Is COVID-19 baby boom a myth? How relationships might be tested during the pandemic

Is COVID-19 baby boom a myth? How relationships might be tested during the pandemic
CALGARY — As Canadians face the possibility of being alone with their significant other for the foreseeable future, some say marital discord is more likely than the kind of intimacy that would lead to a baby boom nine months from now.

Is COVID-19 baby boom a myth? How relationships might be tested during the pandemic

Fertility startup promises to measure women's fertility through at-home AMH tests

Fertility startup promises to measure women's fertility through at-home AMH tests
Caitlin Blaney always dreamed of being a mom. But thoughts of having children got put aside while she pursued her education to become a clinical psychologist. 

Fertility startup promises to measure women's fertility through at-home AMH tests

Medications Put Older People At Severe COVID-19 Risk

The researchers recommended future case-control studies in patients with COVID-19 infections to further confirm chronic therapy with ACEIs or ARBs may raise the risk for severe outcomes.    

Medications Put Older People At Severe COVID-19 Risk